Get the Stockscreener App
15.49
1.71%
0.26
Denali Therapeutics Inc stock is traded at $15.49, with a volume of 2.74M.
It is up +1.71% in the last 24 hours and up +11.68% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$15.23
Open:
$15.37
24h Volume:
2.74M
Relative Volume:
1.77
Market Cap:
$2.26B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-5.4351
EPS:
-2.85
Net Cash Flow:
$-402.10M
1W Performance:
+5.37%
1M Performance:
+11.68%
6M Performance:
-25.28%
1Y Performance:
-35.16%
1-Day Range:
$15.31
$16.19
1-Week Range:
$14.15
$16.19
52-Week Range:
$10.57
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
15.49 | 2.17B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy - MSN
Can Denali Therapeutics Inc. Regain Lost Ground This Quarter2025 Price Targets & Smart Swing Trading Alerts - newsyoung.net
Can Denali Therapeutics Inc. be the next market leaderEarnings Risk Report & Safe Capital Growth Tips - thegnnews.com
Is Denali Therapeutics Inc. stock technically oversold2025 EndofYear Setup & Low Drawdown Trading Techniques - sundaytimes.kr
BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target - MSN
Why Denali Therapeutics Shares Are Slipping - TipRanks
Is Denali Therapeutics Inc. subject to activist investor interestTrade Volume Report & AI Optimized Trade Strategies - thegnnews.com
Denali Therapeutics Inc. Stock Approaches Key Moving Average2025 Valuation Update & Community Verified Swing Trade Signals - sundaytimes.kr
Denali Therapeutics COFO Schuth sells $39884 in stock By Investing.com - Investing.com Canada
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26 - MSN
Denali therapeutics’ Ho Carole sells $52k in stock - Investing.com
Denali Therapeutics COFO Schuth sells $39884 in stock - Investing.com
Science Spotlight: How Denali’s CNS-penetrant amyloid mAb may avoid ARIA - BioCentury
XTX Topco Ltd Lowers Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Elliott Wave Theory Predicts Pullback in Denali Therapeutics Inc.July 2025 Reactions & Community Consensus Picks - beatles.ru
Is now a turning point for Denali Therapeutics Inc.July 2025 Big Picture & Safe Entry Momentum Stock Tips - Newser
What makes Denali Therapeutics Inc. stock price move sharplyJuly 2025 Earnings & Smart Investment Allocation Insights - Newser
Earnings visualization tools for Denali Therapeutics Inc.Weekly Profit Summary & Weekly Momentum Picks - Newser
Technical signs of recovery in Denali Therapeutics Inc.Dividend Hike & Weekly Consistent Profit Watchlists - Newser
Denali Soars 11% on Biotech Sector Turmoil: What’s Fueling This Surge? - AInvest
Using data filters to optimize entry into Denali Therapeutics Inc.Stock Trading Session Highlights and Summary - Newser
Denali Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowSummary of Consistent Growth Stock Picks - Newser
Denali Therapeutics shares fall 3.52% intraday after reporting mixed Q2 2025 results and regulatory updates. - AInvest
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Denali Therapeutics: Advancements in CNS Delivery and Strategic Market Positioning Drive Buy Rating - TipRanks
Denali Therapeutics: Promising Developments and Regulatory Momentum Drive Buy Rating - TipRanks
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - The Manila Times
Denali Therapeutics reports Q2 EPS (72c), consensus (74c) - TipRanks
Denali Therapeutics: Promising Pipeline and Regulatory Progress Justify Buy Rating - TipRanks
Denali Therapeutics Inc. SEC 10-Q Report - TradingView
Denali Therapeutics Q2 2025 Financial Results and Business Highlights: Tividenofusp Alfa BLA Accepted for Priority Review, DNL126 Accelerated Approval Path Aligned, and More. - AInvest
FDA Fast-Tracks Denali's Breakthrough Hunter Syndrome Drug as Pipeline Expands - Stock Titan
Possible Bearish Signals With Denali Therapeutics Insiders Disposing Stock - 富途牛牛
BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Denali Therapeutics (DNLI) to Release Quarterly Earnings on Thursday - Defense World
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? - The Globe and Mail
Is Denali Therapeutics Inc. a good long term investmentMaster stock selection with insider knowledge - Jammu Links News
How strong is Denali Therapeutics Inc. company’s balance sheetCapitalize on momentum stocks before they peak - Jammu Links News
What are Denali Therapeutics Inc. company’s key revenue driversInvest smarter with daily market updates - Jammu Links News
What institutional investors are buying Denali Therapeutics Inc. stockFree Technical Analysis Support - Jammu Links News
What is Denali Therapeutics Inc. company’s growth strategyConsistent triple-digit returns - Jammu Links News
Is Denali Therapeutics Inc. stock overvalued or undervaluedAchieve unparalleled market performance - Jammu Links News
Does Denali Therapeutics Inc. stock perform well during market downturnsMaximize gains with expert trading strategies - Jammu Links News
How does Denali Therapeutics Inc. generate profit in a changing economyMarket-leading profit generation - Jammu Links News
Backtesting results for Denali Therapeutics Inc. trading strategiesForecast Model for Intraday Buy Signals - Newser
How volatile is Denali Therapeutics Inc. stock compared to the marketFree Daily Trading Room Entry - Jammu Links News
What is the risk reward ratio of investing in Denali Therapeutics Inc. stockSky-high return potential - Jammu Links News
Is Denali Therapeutics Inc. a growth stock or a value stockAccelerated financial growth - Jammu Links News
What are analysts’ price targets for Denali Therapeutics Inc. in the next 12 monthsInvest smarter with cutting-edge analytics - Jammu Links News
Is it the right time to buy Denali Therapeutics Inc. stockTransform your portfolio with high-yield stocks - Jammu Links News
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation - MSN
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Denali Therapeutics Inc Stock (DNLI) Insider Trading
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):